Tilray Brands Inc is a global leader in the cannabis industry, specializing in the cultivation, production, and distribution of a diverse range of cannabis products. The company operates across various segments, including medical and recreational cannabis, as well as hemp-derived wellness products. Tilray focuses on innovation and quality, offering a portfolio that encompasses various formats such as dried flower, oils, edibles, and beverages. In addition to its core cannabis business, Tilray is dedicated to advancing research, education, and consumer awareness within the rapidly evolving market, positioning itself as a key player in the development and expansion of cannabis-related offerings worldwide. Read More
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts.
But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
Tilray, with core cannabis ops in Canada, has a diversified footprint in the U.S. due to federal restrictions that exclude TLC, but has positionied itself for future expansion.
Shares of cannabis company Tilray Brands (NASDAQ:TLRY)
fell 5.7% in the afternoon session after a recent rally in cannabis stocks, fueled by hopes of federal marijuana rescheduling in the U.S., reversed course.
Shares of cannabis company Tilray Brands (NASDAQ:TLRY)
jumped 5.5% in the afternoon session after the company announced the launch of three new EU-GMP certified medical cannabis strains in Germany.
NEW YORK and LEAMINGTON, Ontario, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced that it received written notice from the Nasdaq Stock Market, LLC (“Nasdaq”) confirming that Tilray is again in compliance with Nasdaq’s minimum bid price requirement set forth in 5450(a)(1) of the Nasdaq Listing Rules. To achieve this, the Company’s shares were required to close at $1.00 or higher for at least 10 consecutive trading days. According to Nasdaq’s notice, Tilray maintained a closing bid price of at least $1.00 for 10 consecutive trading days from August 13, 2025 to August 26, 2025, thereby meeting the minimum bid price requirement. As a result, Nasdaq has closed the matter.
Shares of cannabis company Tilray Brands (NASDAQ:TLRY)
fell 5.8% in the morning session after investors took profits after a significant rally in the previous session.
Shares of cannabis company Tilray Brands (NASDAQ:TLRY)
jumped 3.2% in the morning session after the cannabis sector experienced a broad rally fueled by growing optimism for U.S. cannabis reform, further bolstered by a bullish update from a Jefferies analyst.
Shares of Tilray Brands are trading higher Tuesday. The cannabis sector is experiencing a broad rally fueled by growing optimism for U.S. cannabis reform.
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Bernstein said in a note that while Netflix remains the undisputed leader in long-form content, YouTube increased its share of streaming by two percent, while Netflix’s total U.S. engagement share declined by a percent.
Pharmaceuticals and cannabis lifestyle company, Tilray Brands Inc. (NASDAQ: TLRY), rallied 20.87% on Monday and is now showing no signs of slowing down, with another 4.32% gain after hours, as broad-based tailwinds begin to align in the company's favor.
Shares of cannabis company Tilray Brands (NASDAQ:TLRY)
jumped 18.6% in the morning session after Jefferies raised its price target on the stock amid growing optimism over a potential shift in U.S. federal cannabis policy.
Shares of Tilray Brands are trading sharply higher Monday morning. The stock is being bolstered by a positive note from Jefferies and growing optimism around significant U.S. cannabis reform this year.
Tilray's stock rally is fueled by market anticipation of a U.S. cannabis rescheduling decision, a key catalyst for the entire cannabis sector's future.
